MedDataX Logo

A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

NCT ID: NCT01913301

Last Updated: 2013-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

134 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to gather information regarding the safety and effectiveness of an investigational drug called Alagebrium when used treating Heart Failure in relation to exercise tolerance after 6 months in the trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diastolic Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alagebrium

Group Type EXPERIMENTAL

Alagebrium

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alagebrium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females 50 years of age or older.
2. Diagnosis of diabetes OR a diagnosis of hypertension requiring therapy.
3. Echocardiographic ejection fraction ≥ 45% verified within 1 year prior to baseline, assuming no intercurrent cardiac event between the echo and screening.
4. Echocardiographic evidence of diastolic dysfunction as defined by an E/E' ≥ 12 determined within 1 year prior to baseline; sinus rhythm required at time of echo.
5. Previous hospitalization due to heart failure OR a current or previous BNP ≥ 100 pg/mL.
6. New York Heart Association (NYHA) functional class II-IV.
7. At least 1 month between hospitalization for heart failure and randomization.
8. Stable doses of heart failure medications (diuretics, ACE inhibitors, ARB's, beta-adrenergic antagonists, aldosterone antagonists) for at least 1 month prior to randomization.
9. Able to understand content of and willing to provide written informed consent.
10. Agree to use adequate contraception during the study if premenopausal. -

Exclusion Criteria

1. Ejection fraction \< 45%.
2. Screening Six-minute walk test \> 450 meters or \< 100 meters
3. Clinically significant cardiac valvular disease (mitral regurgitation (MR) \> grade I, aortic insufficiency (AI) \> grade 1, mitral stenosis (MS), aortic stenosis (AS)).
4. History of stroke, any sequelae of a transient ischemic attack (TIA), or reversible ischemic neurological defect (RIND) within 6 months prior to screening.
5. History of acute myocardial infarction within 6 months prior to screening.
6. Severe COPD as defined by O2 or steroid dependence.
7. History of systemic inflammatory or collagen vascular disease.
8. Active and or treated malignancies within 12 months prior to Visit 1 with the exception of basal cell carcinoma.
9. Any significant systemic illness(es) or medical condition(s) that could lead to difficulty complying with the protocol; or any concurrent condition(s) which, in the investigator's opinion, would prohibit the subject from completing the study, or would not be in the best interest of the subject.
10. Estimated glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m² as calculated by Modification of Diet in Renal Disease (MDRD) study equation \[MDRD = 186 X serum creatinine (mg/dl) 1.154 X years -0.203 X (0.742 if female) X (1.210 if African American)\].
11. Liver function tests (SGOT and/or SGPT) \> 2.5 times the upper limit of normal range.
12. Hb \< 10 g/dL.
13. Use of any investigational drug(s) within 30 days prior to screening.
14. Previous exposure to alagebrium.
15. Known seropositivity for HIV or hepatitis C, or presence of hepatitis B surface antigen.
16. Pregnancy or active breast-feeding. Urine pregnancy tests will be performed on all women who are not post-menopausal for at least 1 year.

\-
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardiovascular Clinical Sciences Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALT-711-0530

Identifier Type: -

Identifier Source: org_study_id